MRK

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly period ended June 30, 2007. Schering-Plough is a global science-based company operating in three segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health. The company is currently in the "Build the Base" phase of its strategic Action Agenda, focusing on growing the business and expanding its product portfolio. A significant strategic development during this period was the announcement of the planned acquisition of Organon BioSciences N.V. for approximately €11.0 billion.

Key Financial Metrics

Note: Net sales exclude the sales of the Merck/Schering-Plough cholesterol joint venture (VYTORIN and ZETIA), which are recorded as equity income.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 13% ($360 million) for the quarter and 15% ($784 million) for the six months compared to the same periods in 2006. Growth was driven by strong performance in Prescription Pharmaceuticals (up 13% QoQ) and favorable foreign exchange impacts (3% for the quarter, 4% for six months).
• Profitability Surge: Net income available to common shareholders more than doubled, rising from $237 million to $517 million for the quarter and from $587 million to $1.06 billion for the six months. This was primarily driven by a significant increase in equity income from the cholesterol joint venture.
• Equity Income: Equity income from the cholesterol joint venture increased 38% to $490 million for the quarter and 47% to $978 million for the six months, reflecting continued sales growth of VYTORIN and ZETIA.
• Expense Increases: Research and Development (R&D) expenses rose 29% for the quarter and 38% for the six months, partly due to $60 million and $156 million in upfront licensing payments, respectively. Selling, General, and Administrative (SG&A) expenses increased 11% due to higher promotional spending.
• Special Charges: Special and acquisition-related charges decreased significantly to $11 million for the quarter and $12 million for the six months, compared to $80 million in the prior year periods (which included manufacturing streamlining costs).

Guidance, Outlook, and Risks

• Outlook: Management anticipates continued sales growth from VYTORIN and ZETIA in 2007. Gross margins are expected to improve for the full year due to manufacturing streamlining savings and product mix, though the second half may be slightly lower due to seasonality. R&D expenses are expected to grow faster than adjusted net sales as clinical trials expand.
• Acquisition Impact: The planned acquisition of Organon BioSciences is expected to be accretive to earnings per share in the first full year, excluding purchase-accounting adjustments. The company expects to achieve $500 million in annual synergies over three years.
• Tax Rate: The full-year 2007 tax rate is expected to be in the mid-teens on a GAAP basis.
• Key Risks:
  • Product Dependence: Significant reliance on the cholesterol franchise (VYTORIN/ZETIA) and other key products like REMICADE and NASONEX.
  • Regulatory Environment: Ongoing scrutiny from the FDA, including a Consent Decree regarding manufacturing practices, and potential impacts from pharmacovigilance inspections.
  • Legal and Tax: Exposure to litigation regarding pricing practices (AWP), patent challenges, and significant unrecognized tax benefits ($924 million at Jan 1, 2007) following the adoption of FIN 48.
  • Market Risk: Exposure to foreign currency fluctuations (hedged partially via a €7.7 billion option) and interest rate changes.

Investor Verification Checklist

• Joint Venture Accounting: Verify the specific profit-sharing mechanics of the Merck/Schering-Plough cholesterol joint venture, as a large portion of the company's profit is derived from equity income rather than direct sales.
• Organon Acquisition Financing: Confirm the status of the €11.0 billion bridge financing facility and the potential impact on credit ratings (currently under review for possible downgrade).
• Tax Liabilities: Review the $259 million reduction in retained earnings due to the adoption of FIN 48 and the status of the $924 million in unrecognized tax benefits.
• R&D Spend Quality: Assess the sustainability of R&D growth, noting that a significant portion ($156 million in six months) was due to non-recurring upfront licensing payments.
• Regulatory Compliance: Monitor updates on the FDA Consent Decree and the resolution of the Massachusetts Investigation settlement payments.